Self-assembled dextrin nanogel as protein carrier : controlled release and biological activity of IL-10 by Carvalho, Vera et al.
ARTICLE
Self-Assembled Dextrin Nanogel as Protein
Carrier: Controlled Release and Biological
Activity of IL-10
Vera Carvalho,1 Pedro Castanheira,2 Pedro Madureira,3,4 Sı´lvia A. Ferreira,1
Carla Costa,5 Joa˜o P. Teixeira,5 Carlos Faro,2,6 Manuel Vilanova,3,4 Miguel Gama1
1IBB, Institute for Biotechnology and Bioengineering, Centre of Biological Engineering,
Universidade do Minho, Campus de Gualtar, 4710-057 Braga, Portugal;
telephone: (þ351) 253 604 400; fax: (þ351) 253 678 986; e-mail: fmgama@deb.uminho.pt
2Biocant, Molecular Biotechnology Unit, Parque Tecnolo´gico de Cantanhede, Cantanhede,
Portugal
3ICBAS, Instituto de Cieˆncias Biome´dicas de Abel Salazar, Porto, Portugal
4IBMC, Instituto de Biologia Molecular e Celular, Porto, Portugal
5Environmental Health Department, Portuguese National Institute of Health, Porto, Portugal
6Departament of Life Sciences, Universidade de Coimbra, Coimbra, Portugal
Received 15 December 2010; revision received 23 February 2011; accepted 28 February 2011
Published online 9 March 2011 in Wiley Online Library (wileyonlinelibrary.com). DOI 10.1002/bit.23125
ABSTRACT: Interleukin-10 (IL-10) is an anti-inﬂammatory
cytokine, which active form is a non-covalent homodimer.
Given the potential of IL-10 for application in various
medical conditions, it is essential to develop systems for
its effective delivery. In previous work, it has been shown
that a dextrin nanogel effectively incorporated and stabilized
rIL-10, enabling its release over time. In this work, the
delivery system based on dextrin nanogels was further
analyzed. The biocompatibility of the nanogel was compre-
hensively analyzed, through cytotoxicity (lactate dehydro-
genase (LDH) release, MTS, Live, and Dead) and
genotoxicity (comet) assays. The release proﬁle of rIL-10
and its biological activity were evaluated in vivo, using
C57BL/6 mice. Although able to maintain a stable concen-
tration of IL-10 for at least 4 h in mice serum, the amount of
protein released was rather low. Despite this, the amount of
rIL-10 released from the complex was biologically active
inhibiting TNF-a production, in vivo, by LPS-challenged
mice. In spite of the signiﬁcant stabilization achieved using
the nanogel, rIL-10 still denatures rather quickly. An addi-
tional effort is thus necessary to develop an effective delivery
system for this cytokine, able to release active protein over
longer periods of time. Nevertheless, the good biocompat-
ibility, the protein stabilization effect and the ability to
perform as a carrier with controlled release suggest
that self-assembled dextrin nanogels may be useful protein
delivery systems.
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Introduction
Interleukin-10 (IL-10) is produced by various cell types
including T and B cells, monocytes, and macrophages
(Moore et al., 2001; Pestka et al., 2004). This cytokine is
highly pleiotropic displaying biological activities that
include: inhibition of several cytokines synthesis, including
IL-1, IL-2, IL-3, IL-6, IL-8, IL-12, tumor necrosis factor a
(TNF-a), and interferon g (de Waal Malefyt et al., 1991a);
immunosuppressive effects on monocytes/macrophages
(Bogdan et al., 1991; Fiorentino et al., 1991; Gazzinelli
et al., 1992); as well as immunostimulatory activity on a
broad range of cell types, including T cells (MacNeil et al.,
1990), B cells (Defrance et al., 1992), and mast cells.
Furthermore, IL-10 down-regulates constitutive and IFN-g-
or IL-4-induced class II major histocompatibility complex
molecules expression on monocytes, dendritic cells, and
Langerhans cells (de Waal Malefyt et al., 1991b; Groux et al.,
1998) as well as adhesion and co-stimulatory molecules on
antigen-presenting cells (Creery et al., 1996; Willems et al.,
1994). It also suppresses the release of reactive oxygen
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intermediates (Bogdan et al., 1991; Fiorentino et al., 1991).
IL-10 has thus a strong anti-inﬂammatory activity, acting as
a general suppressive factor of immune responses. It might
be therefore an effective agent to prevent LPS toxicity in
vivo, as previously demonstrated in mice (Gerard et al.,
1993; Howard et al., 1993; Leon et al., 1999).
Due to its immunoregulatory properties, this cytokine has
been proposed to be used in vaccination (Berzofsky et al.,
2001) or in the treatment of allergies (Pullerits, 2002),
infectious diseases (Hubel et al., 2002), acute and chronic
inﬂammatory diseases (Asadullah et al., 2003), among
pathologic conditions. Usually, proteins of this kind are
expensive to produce on a large scale and denature easily,
loosing their bioactivity, thus having a quite short half-life in
vivo. So, it is essential to develop new delivery systems that
would allow effective therapeutic effects at a minimum
dosage. A promising method is protein encapsulation by
polymeric nanogels (or hydrogel nanoparticles), which, by
trapping them in a hydrated polymer-network, minimize
denaturation, enabling slow-release, while maintaining an
effective concentration for the necessary period of time (Kim
et al., 2009; Leonard et al., 2004; Murthy et al., 2002, 2003).
In previous work (Carvalho et al., 2010), a dextrin self-
assembled nanogel was used to effectively incorporate a
recombinant biologically active mutated murine IL-10 form
(rIL-10) and shown to enable its release over time. In this
work, we present a further characterization of the complex
nanogel/rIL-10, including the nanogel’s cellular cytotoxicity
and the in vivo rIL-10 release from the nanogel complex,
after subcutaneous (sc) injection in C57BL/6 mice. The
effect of rIL-10 and nanogel/rIL-10 administration before
lipopolysaccharide (LPS) challenge (endotoxin-induced
shock) in C57BL/6 mice, assessed by systemic TNF-a
release, was also analyzed.
Material and Methods
All reagents used were of laboratory grade and purchased
from Sigma–Aldrich (MO), unless stated otherwise. IL-10
and TNF-a were quantiﬁed by a enzyme-linked immuno-
sorbent assay (ELISA) commercial kit, Mouse IL-10 ELISA
Ready-SET-Go! and Mouse TNF-a ELISA Ready-SET-Go!
(eBioscience, San Diego, CA, USA), respectively, following
the manufacturer’s instructions.
Preparation of Nanogel and Complex Nanogel/rIL-10
Dextrin nanogel and the complex nanogel/rIL-10 were
prepared as previously described (Carvalho et al., 2010).
Brieﬂy, the self-assembled nanogels were obtained by
dissolving the lyophilized dextrin-VMA-SC16 in cell culture
medium or phosphate-buffered saline (PBS) pH 7.4
(2.7mM KCl, 137mM NaCl, 10mM HPO4  2H2O,
2mM KH2PO4), at a concentration of 1.0mg/mL. The
dissolution was accomplished after approximately 16 h at
room temperature, with stirring. The nanogel formation was
conﬁrmed by dynamic light scattering (DLS), as described
previously (Carvalho et al., 2010; Goncalves and Gama,
2008; Goncalves et al., 2007, 2010). The concentration was
adjusted to 0.4, 0.1, and 0.05mg/mL by dilution of the 1mg/
mL suspension.
The complex nanogel/rIL-10 was formed by dissolving
rIL-10 in cell culture medium or PBS, followed by
dissolution of lyophilized dextrin-VMA-SC16, for approxi-
mately 16 h at room temperature with stirring. The rIL-10
incorporation was conﬁrmed by quantifying the amount of
rIL-10 free in solution using the ELISA commercial kit,
following the manufacturer’s instructions.
All suspensions were sterilized by ﬁltration through a
0.45mm membrane.
Cell Cultivation
Mouse Embryo Fibroblasts 3T3
Mouse embryo ﬁbroblasts 3T3 (ATCC CCL-164) were
grown in Dulbecco’s modiﬁed Eagle’s medium supplemen-
ted with 10% newborn calf serum (Invitrogen, CA) and
1mg/mL penicillin/streptavidin (DMEM complete medium
[cDMEM]) at 378C in a 95% humidiﬁed air containing 5%
CO2. At 80% conﬂuency, 3T3 ﬁbroblasts were harvested
with 0.05% (w/v) trypsin-EDTA and subcultivated in the
same medium.
Murine Bone Marrow-Derived Macrophages (BMDM)
Macrophages were obtained from mouse bone marrow as
follows: mice were sacriﬁced and femurs and tibias removed
under aseptic conditions. Bones were ﬂushed with Hanks’
balanced salt solution. The resulting cell suspension
was centrifuged at 500 g and resuspended in RPMI
1640medium supplemented with 10mMHEPES, 10% heat-
inactivated fetal bovine serum (FBS), 60mg/mL penicillin/
streptavidin, 0.005mM b-mercaptoethanol (RPMI com-
plete medium [cRPMI]), and 10% L929 cell conditioned
medium (LCCM). To remove ﬁbroblasts or already
differentiated macrophages, cells were cultured, on cell
culture dishes (Sarstedt, Canada), overnight at 37 8C in a 5%
CO2 atmosphere. Then, non-adherent cells were collected
with warm cRPMI, centrifuged at 500 g, distributed in 96-
well plates (Sarstedt, Canada) at a density of 1 105 cells/
well, and incubated at 37 8C in a 5% CO2 atmosphere. Four
days after seeding, 10% of LCCM was added, and the
medium was renewed on the seventh day. After 10 days in
culture, cells were completely differentiated into macro-
phages. This method allows for the differentiation of a
homogenous primary culture of macrophages that retain
the morphological, physiological, and surface markers
characteristics of these phagocytic cells (Mosmann, 1983;
Tushinski et al., 1982; Zhang et al., 2008).
Evaluation of Nanogel Cellular Cytotoxicity
Cellular cytotoxicity was assessed using the MTS, live and
dead, and comet assays, and by measuring the release
of LDH. Although all these methods are usually used to
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evaluate cell viability, they address different features, namely
the cell integrity or metabolic activity. In our experience,
using the different methods allows a more comprehensive
and consistent detection of cytotoxicity.
Mouse embryo ﬁbroblasts 3T3 were seeded (4 105 cells/
well in a 96-well polystyrene plate or 1 106 cells/well in a
six-well polystyrene plate) and incubated at 378C, 5% CO2
for 2 h. Then, the culture medium was removed and
replaced with cDMEM containing a different concentration
of nanogel suspension (0.05–1mg/mL) and cells further
incubated for 24 or 48 h. In a similar way, on the tenth day of
BMDM differentiation, the culture medium was replaced
with NPs suspensions (0.05–1mg/mL), in cRPMI, and cells
further incubated for 24 or 48 h. Control cells were
incubated with fresh medium and wells containing only
growth medium were used as blanks.
Exceptionally, the culture medium used for the LDH
release assay had only 1% serum and the incubation times
were three and 20 h.
All assays were made with triplicate cell incubations.
MTS Assay
Cellular viability, was assessed by measuring cell concentra-
tion via mitochondrial reduction of the tetrazolium salt
MTS (3-(4,5-dimethyl-2-yl)-5-(3-carboxy-methoxyphenyl)-2-
(4-sulfophenyl)-2H-tetrazolium) in the presence of 5%
phenazinemethosulfate over a 1h incubation period. The
colored reaction product formazan is soluble in the culture
medium and can be measured spectrophotometrically at a
wavelength of 490nm with a reference wavelength of 570nm.
After the incubation time, the culture medium of each
well was replaced with 100mL of fresh culture medium and
20mL of CellTiter 961 AQueous One Solution Reagent
(Promega, CA) was added and the plate further incubated
for 1 h at 378C, 5% CO2, as indicated by the manufacturer.
The amount of soluble formazan produced by cellular
reduction of MTS was measured at 490 nm.
Live and Dead Assay
The LIVE/DEAD1 Viability/Cytotoxicity Kit for mammalian
cells (Invitrogen, CA) was used to determine cell viability. This
kit provides two-color ﬂuorescence cell viability assay, based
on the simultaneous determination of live and dead cells
with two probes that measure intracellular esterase activity
and plasma membrane integrity.
Brieﬂy, after the incubation time, 200mL of a 2mM
calcein AM solution and 4mM ethidium homodimer-1, in
sterile PBS, were added to the wells, incubated for 30 to
45min at 378C, 5% CO2 (as indicated by the manufacturer)
and visualized in a ﬂuorescence microscope.
Lactate Dehydrogenase Release
The Cytotoxicity Detection KitPLUS (LDH) (Roche, Basel,
Switzerland) is a colorimetric assay for quantitating
cytotoxicity/cytolysis by measuring LDH activity released
from damaged cells.
The amount of LDH released was measured using the
Cytotoxicity Detection KitPLUS (LDH) following manufac-
turer’s instructions. In few words, after cell incubation with
nanogel, 100mL of reaction mixture was added to each well
and the plate incubated at room temperature for 9min, in
the dark. Then, 50mL of stop solution was added to each
well and the absorbance of the samples was measured at
492 nm. Three controls were included: background control
(determines the LDH activity in the assay medium) made
with 1% serum culture medium; low control (determines
the LDH activity released from the untreated normal cells)
made with cells incubated with 1% serum culture medium;
and, high control (determines the maximum releasable LDH
activity in the cells) made with cells incubated with 1%
serum culture medium where 5mL of lysis solution was
added before LDH quantiﬁcation.
To determine the percentage cytotoxicity, the average
absorbance values of the triplicate samples and controls were
calculated; the average absorbance value obtained in the
background control was subtracted to the value obtained
using the samples. Cytotoxicity percentage values were
obtained substituting the resulting values in the following
equation:
Cytotoxicity ð%Þ ¼ ðSample valueLow controlÞðHigh controlLow controlÞ  100
Comet Assay
The comet assay (single-cell gel electrophoresis) is a simple
method for detecting DNA damage at the level of individual
cells (Singh et al., 1988). Cells embedded in agarose on a
microscope slide are lysed with detergent and high salt to
form nucleiods containing supercoiled loops of DNA linked
to the nuclear matrix. Electrophoresis at high pH results in
structures resembling comets, observed by ﬂuorescence
microscopy; the intensity of the comet tail relative to the
head reﬂects the number of DNA breaks.
The comet assay was performed as described by Costa
et al. (2008), with some exceptions. Brieﬂy, collected cells
were centrifuged (7500 g for 3min), suspended in 100mL
of 0.6% low-melting-point agarose in PBS and dropped
onto a slide precoated with a layer of 1% normal melting
point agarose and covered with coverslips. Slides were
placed on ice and allowed to solidify. Cover slips were then
removed and slides were immersed in freshly prepared lysing
solution (2.5M NaCl, 100mM Na2EDTA, 10mM TrisBase,
0.25M NaOH, pH 10) for 1 h at 48C, in the dark. After lyses,
slides were placed on a horizontal electrophoresis tank and
the tank ﬁlled with freshly made alkaline electrophoresis
solution (1mMNa2EDTA, 300mMNaOH, pH 13) to cover
the slides, and left for 20min in the dark to allow DNA
unwinding and alkali-labile site expression. Then, electro-
phoresis was carried out for 20min at 30 V and 300mA
(1.13 V/cm) and after, the slides were washed for 10min
with neutralizing solution (0.4M TrisBase, pH 7.5). After
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neutralization, the slides were left to dry overnight in the
dark. Afterwards, the slides were rehydrated for 30min with
ice-cold bidistilled water and stained with ethidium bromide
solution (20 g/mL) for 20min. After staining, the slides were
washed again twice with ice-cold bidistilled water for
20min. Each experimental condition was carried out twice
with mousse embryo ﬁbroblasts 3T3 and once with BMDM,
and one slide was prepared for each sample. A ‘‘blind’’ scorer
examined 100 randomly selected cells in each slide using a
magniﬁcation of 500. The DNA damages were evaluated
by image analysis performed with Comet Assay IV software
(Perceptive Instruments, Haverhill, UK). Data collected
from each cell included tail length (TL), tail intensity, and
tail moment.
In vivo rIL-10 Release From the Nanogel/rIL-10
C57BL/6 mice were purchased from Charles River
Laboratories Espan˜a S. A. (Spain).
Mice were injected with 200mL of nanogel/rIL-10
suspension in PBS (12.5mg/mL rIL-10 and 5mg/mL
nanogel), rIL-10 solution in PBS (12.5mg/mL), nanogel
suspension in PBS (5mg/mL), or PBS via subcutaneous (sc)
route. Blood samples were taken at given intervals of time
and serum concentrations of IL-10 were assayed by ELISA.
In vivo Effects of rIL-10 and Nanogel/rIL-10 in
Endotoxin-Induced Shock Mice
C57BL/6 mice were injected intraperitoneally (i.p.) with
100mg of LPS 30min after an i.p. administration of rIL-10
(2.5mg), nanogel/rIL-10 (1mg nanogel, 2.5mg rIL-10), and
nanogel (1mg). Serum TNF-a levels were determined by
ELISA 1.5 and 6 h after LPS challenge. As controls, serum
TNF-a levels were determined, in mice injected with PBS
with and without LPS challenge.
Data Analysis
Data are presented as means SD of the indicated number
(n) of determinations. Statistical analysis was performed
using the variance analysis method (One way ANOVA).
Signiﬁcant differences between samples were determined
through Dunnet Test.
Results and Discussion
Nanogel Cellular Cytotoxicity Assays
Polymer formulations, including polymer–protein conju-
gates, are ﬁnding increasing clinical use. Synthetic and
natural polymers have been explored as drug carriers,
but many of the polymers used clinically are still non-
biodegradable synthetic polymers (Hreczuk-Hirst et al.,
2001). The proven clinical tolerability of dextrin and readily
degradation by amylases suggest that this polymer might be
ideal for the development of drug carriers (Hreczuk-Hirst
et al., 2001). Furthermore, dextrin is readily excreted due to
its low molecular weight, hence accumulation in the tissues
is unlikely. In this work, dextrin is used to produce self-
assembled nanogels following methodologies described in
previous work (Carvalho et al., 2010; Goncalves and Gama,
2008; Goncalves et al., 2007, 2010).
Self-assembled dextrin nanogels, dispersed in water at a
concentration of 1.0mg/mL, were observed using DLS after
ﬁltration through a 0.45mm membrane. The DLS analysis,
in the intensity distribution, revealed two populations with
roughly 25 and 150 nm (Goncalves and Gama 2008;
Goncalves et al., 2007). The conversion to number
distribution highlighted only the smaller population of
particles, the predominant one. The z-value obtained was
23.6 nm, representative of the average size of polydisperse
colloids. Previously (Goncalves and Gama 2008), the
variation of the hydrodynamic diameter (z-value) and
zeta-potential of the nanogel with pHwas studied and found
to be almost constant and close to zero. Although the low
zeta potential, the nanogel is stable. The stability observed in
a wide range of conditions (the effect of ionic force, pH, and
presence of urea were analyzed and reported elsewhere), can
be attributed to the solvation forces (Goncalves and Gama
2008). Indeed, in the absence of electrostatic repulsive
forces, the colloidal stability may be assigned either to steric
effects, to hydration forces, or the both, counteracting the
attractive van der Waals forces (Fichthorn and Qin, 2006).
In order to evaluate the biocompatibility of the dextrin
nanogel, in vitro experiments were carried out using mouse
embryo ﬁbroblasts 3T3 and bone marrow derived macro-
phages (BMDM). Cytotoxicity, deﬁned as the ‘‘in vitro
evaluation of toxicological risks using cell culture,’’ is a way
to assess the in vitro biocompatibility of materials to be used
in biomedical applications. Biocompatibility assays deal
with the assessment of various aspects of cellular function
such as cell viability and proliferation, loss of membrane
integrity, reduced cell adhesion, biosynthetic activity, and
altered cell morphology (Chiellini et al., 2006). Moreover,
the information gained from these types of investigations
may be used in the design of further in vivo experiments.
Given the concerns related to the possible toxicity associated
to nanoparticulated materials, we found appropriate to
perform a comprehensive characterization of biocompat-
ibility of the nanogel. In this case we address the cytotoxicity
and genotoxicity analysis.
Nanogel was resuspended in culture medium at different
concentrations ranging between 0.05 and 1mg/mL. Cells
were incubated for 24 or 48 h with the nanogel suspensions
and then tested for cell viability and proliferation using
MTS, LDH, Comet, and Live and Dead assays. It should be
noted that the higher concentration used was intentionally
high, as to detect any possible effects caused to the cells by
the nanogel, it must be acknowledged however that such a
concentration is not likely to be reached in any biomedical
application of the material.
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Figure 1A illustrates the MTS absorbance values obtained
for ﬁbroblasts cultured with the nanogel. Fibroblasts in
control wells (wells with cDMEM without nanogel) behave
as expected: the cells adhere after seeding and proliferate,
reaching conﬂuency after 48 h. In wells with the higher
concentration of the nanogel (1mg/mL), cell proliferation is
inhibited, especially after 48 h incubation. In wells treated
with 0.1 and 0.05mg/mL, cells proliferate normally and also
reach conﬂuency after 48 h.
MTS was also used to evaluate BMDM cells viability
(Fig. 1B). In control wells (with cRPMI), the number of cells
is relatively constant over time meaning that cells are kept
alive. As seen with ﬁbroblasts, after 48 h, the absorbance
values are very low in wells treated with the higher
concentration of the nanogel, meaning that cells die to a
signiﬁcant extent after 48 h of incubation. Cells treated with
the lower concentrations (0.1 and 0.05mg/mL) show a
behavior similar to control wells.
To further evaluate the nanogel cytotoxicity, the Live and
Dead1 assay was performed using the nanogel in
concentrations ranging from 0.1 to 1mg/mL. In Figure 2,
ﬂuorescence images of BMDM cells, after 24 or 48 h
incubation with the nanogel are shown. In wells with cRPMI
(control wells) the number of living cells (stained in green) is
far superior to the number of dead cells (stained in red) and
this proportion is maintained over time. When cells are
treated with 1mg/mL of the nanogel, the number of cells
stained in red augments, especially after 48 h incubation.
Lower concentrations of the nanogel did not alter
signiﬁcantly the number of living cells comparatively to
control wells and the number of green live cells is fairly the
same over time. Similar results were obtained using mouse
embryo ﬁbroblasts 3T3 (images not shown).
Table I reports the percentage of the nanogel cytotoxicity
in mouse embryo ﬁbroblasts 3T3 and BMDM, measured by
the LDH activity released from damaged cells.
In agreement with the previous results, 1mg/mL of the
nanogel showed higher toxicity toward ﬁbroblasts. After
20 h incubation, 0.1 and 0.05mg/mL of the nanogel did not
show any cytotoxicity. Cytotoxicity was also measured in
BMDM cultures by measuring LDH activity released from
damaged cells (Table I) and conﬁrmed the previous results.
The genotoxicity of a material may be measured by
analyzing the damage caused on DNA. The comet assay or
single-cell gel electrophoresis assay is a rapid, sensitive and
relatively simple procedure to detect DNA damage (Singh
et al., 1988). It combines the simplicity of biochemical
techniques for detecting DNA single strand breaks (strand
breaks and incomplete excision repair sites), alkali-labile
sites and cross-linking, using the single cell approach. The
advantages of the comet assay, relative to other genotoxicity
tests, include its high sensitivity for detecting low levels of
both single and double stranded breaks in damaged DNA,
the requirement for small numbers of cells per sample,
ﬂexibility, low cost, and ease of application (Brendler-
Schwaab et al., 2005; Collins et al., 1997, 2008). Moreover,
the comet assay is arguably one of the most widely used tests
for genotoxicity available (Anderson and Plewa 1998;
Anderson et al., 1998), being already described as a
reproducible assay to evaluate nanoparticles genotoxicity
(Collins et al., 1997), and suggested as a diagnostic tool for
clinical management of cancer (Collins et al., 2008). The
genotoxicity of a nanomaterial may result from a direct
interaction with DNA, or from an indirect response caused
by several factors, including surface stress through direct
particle inﬂuences on DNA, the release of toxic ions from
soluble nanoparticles, or generation of oxidative stress
(Barnes et al., 2008).
The comet assay is based on the ability of negatively
charged loops/fragments of DNA to be drawn through an
agarose gel, in response to an electric ﬁeld. The extent of
DNA migration depends directly on the DNA damage
present in the cells (Collins et al., 2008). It should be pointed
out that DNA lesions consisting of strand breaks after
treatment with alkali, either alone or in combination with
certain enzymes (as endonucleases) increases DNA migra-
tion, whereas DNA–DNA and DNA–protein cross-links
result in retarded DNA migration compared to those in
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Figure 1. MTS absorbance results. A: Nanogel incubation with mouse embryo ﬁbroblasts 3T3 and (B) nanogel incubation with BMDM. Shown are mean SD values (n¼ 3).
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concurrent controls (Tice et al., 2000). In the procedure
described, a suspension of cells, previously treated with
different concentrations of the nanogel, was mixed with low
melting agarose and spread in slides precoated with normal
melting point agarose. After lysis of cells with detergent at
high salt concentration, DNA unwinding and electrophor-
esis was carried out speciﬁcally at pH 13 (Miyamae et al.,
1997). When an electric ﬁeld is applied, the DNA migrates
out of the cell, in the direction of the anode, looking like a
comet. The size and shape of the comet is related with the
extent of the DNA damage (Fairbairn et al., 1995).
Although information on different comet assay para-
meters has been collected, data presented here concerns
only TL as this was the parameter that offered the more
reproducible results in duplicates.
Results show that DNA damage assessed by means of TL
increases with concentration and time of exposure to
nanogel in both studied cell types (3T3 ﬁbroblasts and
BMDM). Figure 3 presents observed means of TL in each
experimental condition.
The overall obtained results indicate a high level of
cytocompatibility for the lower concentrations of the
nanogel (0.1 and 0.05mg/mL), under the conditions tested
and for the two cell lines used. The results obtained with the
higher concentrations, especially 1mg/mL, indicated that, in
the assays conditions, nanogel can present moderate
cytotoxicity, inhibiting mouse embryo 3T3 ﬁbroblasts
proliferation and diminishing BMDM viability, although
no signiﬁcant DNA damages were detected.
In vivo Release and Biological Activity of rIL-10
Aiming at achieving an effective protein delivery in vivo,
carriers such as liposomes, polymer micelles, and micro or
nanogels have been developed (Branco and Schneider, 2009;
Devalapally et al., 2007; Haag and Kratz, 2006; Kim et al.,
2009; Lukyanov and Torchilin, 2004; Nair and Laurencin,
2006; Nayak and Lyon, 2005). Among them, nanometer-
sized polymer hydrogels (nanogels) have attracted growing
interest. By trapping proteins in a hydrated polymer-
network, nanogels minimize denaturation, simultaneously
allowing a slow, continuous, and controlled release of the
protein, ideally maintaining an effective concentration for
the necessary period of time (Kim et al., 2009; Leonard et al.,
2004; Murthy et al., 2002, 2003). Nanocarriers enable
localized and speciﬁc targeting to their intended tissues or
cells, thereby allowing the use of lower drug doses
(Devalapally et al., 2007). The ideal protein delivery system
should be able to enhance the protein solubility; allow its
controlled and sustained release; improve biodistribution
and targeting of the diseased tissue, in vivo (Tan et al., 2010).
In addition, the nanocarrier must not compromise the
bioactivity of the protein. On the other hand, binding/
trapping must be stable enough as to allow release only at the
site of action, in a sustained, controlled way. Another critical
Figure 2. Fluorescence photographs of BMDM cells incubated with the nanogel (0.1–1mg/mL) stained with LIVE/DEAD1 Viability/Cytotoxicity Kit for mammalian cells. Live
cells are stained in green and dead cells stained in red. [Color ﬁgure can be seen in the online version of this article, available at http://wileyonlinelibrary.com/bit]
Table I. Nanogel cytotoxicity in mouse embryo ﬁbroblasts 3T3 and
BMDM, evaluated by Cytotoxicity Detection KitPLUS (LDH).
Nanogel
(mg/mL)
Cytotoxicity (%) SD (%)
3 h 20 h
3T3 ﬁbroblasts BMDM 3T3 ﬁbroblasts BMDM
1 9.9 4 0.5 0 39.8 15 6.5 3
0.4 2.8 2 ND 15 5 ND
0.1 ND ND ND ND
0.05 ND ND ND ND
Cytotoxycity percentage values where obtained as described in the
experimental section. Values shown correspond to mean SD (n¼ 3).
ND, not detected.
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impediment of cytokine therapy is the systemic adverse
effects that can arise from the administration of high doses
of cytokines. Hence, a delivery system that could enable a
slow-release in vivo of a given cytokine may improve
treatment, avoiding unwanted side-effects whereas improv-
ing therapeutic efﬁcacy.
The rIL-10 incorporation by the nanogel suspension was
described in a previous work (Carvalho et al., 2010), where it
has been shown that a part of the encapsulated cytokine may
be displaced by adding FBS to the colloidal suspension.
There, it was also shown that the nanogel signiﬁcantly
stabilizes rIL-10, as evaluated by circular dichroism.
However, denaturation of the cytokine still proceeds, even
when complexed in the nanogel. rIL-10 is a very unstable
protein with a predicted half-life of 4.4 0.7 days, at 378C in
PBS, based on the evaluation of the mean residual ellipticity
(u) variation, at 222 nm (Carvalho et al., 2010). Probably,
the release rate is dependent on the properties of the protein
incorporated in the dextrin nanogel. Properties such as
hydrophobicity, long-term stability and binding afﬁnity can
condition the incorporation and the release proﬁle from
(nano)hydrogels (Lee and Mooney, 2001; Lee and Yuk,
2007). This possibility will be exploited in forthcoming work
using other bioactive proteins.
Indeed, a protein release system based on cholesterol-
bearing pullulan (CHP)-based nanogels (a nanogel similar
to the one used in this work) for interleukin-12 (IL-12) was
described recently (Hasegawa et al., 2009; Shimizu et al.,
2008). IL-12 is an immunostimulatory cytokine that can
suppress not only tumor growth and metastasis, but also
infection and allergy. However, as for IL-10, it is difﬁcult
to maintain its plasma concentration at an effective level
due to its short half-life in vivo. The CHP-based nanogels
effectively incorporated IL-12 and maintained relatively
high serum IL-12 levels in plasma after sc injection in mice
for 12–24 h. Additionally, tumor growth was successfully
inhibited by weekly administrations of CHP/IL-12 complex.
Later on, the same group (Hasegawa et al., 2009) prepared
raspberry-like assembled nanogels (A-CHPNG) by cross-
linking an acrylate group-modiﬁed cholesterol-bearing
pullulan nanogel with thiol group-modiﬁed poly(ethylene
glycol) (PEGSH). They showed that, even in the presence of
a high concentration of BSA (50mg/mL), A-CHPNG did
not release IL-12 for at least 72 h. As with the nanogel/rIL-10
complex, the IL-12 release is driven mainly by an exchange
mechanism between IL-12 and BSA proteins and this
exchange seem to be minimized by PEG chain which offer a
structural stability and a protein-repellent property. This
modiﬁcation also allowed the maintenance of high plasma
IL-12 levels for 72 h.
A similar approach was attempted in this work using
the nanogel/rIL-10 complex. In vivo kinetics of rIL-10
release was examined by administrating nanogel/rIL-10 into
mice. Figure 4 illustrates the levels of IL-10 measured in the
sera after administration of rIL-10 and nanogel/rIL-10.
After a sc injection with a free rIL-10 solution, the IL-10
concentration in the sera peaked at 1 h, followed by a rapid
decrease. In contrast, serum IL-10 levels remained relatively
constant in the nanogel/rIL-10 treated mice (about 13% of
the concentration observed using free IL-10, 1 h after
administration). It is noteworthy that a sc injection with
nanogel/rIL-10 complex resulted in a sustained-release in
vivo of the cytokine, whereas the administration of free rIL-
10 solution resulted in a rapid decrease of serum IL-10 levels.
However, it is noticeable that the release of the protein
from the nanogel occurs to a limited extent and although a
lower initial concentration of rIL-10 was expected when
using the nanogel formulation, the aimed protein release
over a wide time frame was not observed. Interestingly, it is
possible to observe that while a quick concentration
reduction occurs over time in the case of the free protein
administration, the nanogel formulation allows a more
constant concentration to be obtained, a highly desirable
feature. However, the time frame of the observed release is
still limited. This effect is likely due to the instability of the
cytokine. We suppose that a strong interaction of the
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cytokine may occur, likely involving a denatured fraction of
rIL-10 and the hydrophobic domains inside the nanogel, as
observed previously, leading to the incomplete release of the
cytokine. Other proteins—more stable—may perform
better.
Endotoxin from Gram-negative bacteria is a major
causative agent of septic shock pathogenesis, and injection
of LPS is a widely used experimental model of systemic
inﬂammation (Gerard et al., 1993; Howard et al., 1993; Leon
et al., 1999; Tang et al., 2010). The toxic effects of LPS are
mostly related to macrophage activation leading to the
release of multiple inﬂammatory mediators, as TNF-a and/
or IL-1. Previously, we demonstrated that rIL-10 as well as
the complex nanogel/rIL-10, efﬁciently blocked the in vitro
production of TNF-a by LPS-activated BMDMs (Carvalho
et al., 2010). So, rIL-10 might be an efﬁcient agent to
diminish LPS toxicity in vivo.
To assess the in vivo effects of rIL-10 and nanogel/rIL-10
administration on LPS-induced TNF-a release, rIL-10,
nanogel/rIL-10 complex and nanogel were given i.p. to
C57BL/6 mice 30min before the i.p. administration of
100mg LPS. Blood samples were taken 1.5 and 6 h after LPS
challenge and serum TNF-a quantiﬁed by ELISA (Fig. 5). As
controls, mice were also pretreated with PBS (with and
without LPS challenge).
Sera from blood collected 1.5 h after LPS challenge
indicates a substantial reduction in circulating TNF-a in
animals receiving rIL-10 and nanogel/rIL-10 prior to LPS
administration, comparing to animals receiving the nanogel
or PBS. The inhibition of circulating TNF-a is directly
related to the protection of mice from lethal endotoxemia
(Tang et al., 2010; Wan et al., 2006), an effect that could be
observed both with soluble and the nanogel/rIL-10 complex,
contributing to the protection against lethal endotoxemia by
inducing the suppression of TNF-a.
Despite the incomplete release of rIL-10 from the
complex nanogel/rIL-10, it is noticeable that the available
protein is capable to efﬁciently diminish TNF-a production
to levels achieved with the soluble protein. Therefore, it can
be assumed that the rIL-10 is been released from the
complex nanogel/rIL-10 in biologically signiﬁcant amounts.
Further characterization of the rIL-10 - nanogel interation is
required to better evaluate the potential of this formulation.
The nanogels may perform more effectively with other
proteins (unpublished ongoing work).
Conclusions
The therapeutic potential of many pharmaceutical proteins
could proﬁt considerably from the availability of controlled
released systems for the constant release of the intact
biologically active protein. IL-10 has potential application in
various medical ﬁelds, such as in acute inﬂammatory
diseases, so it is important to develop IL-10 release systems,
in order to prevent IL-10 denaturation and to enable a slow
controlled release.
We have previously demonstrated that the dextrin
nanogel enhances rIL-10 stability and allows the release of
biologically active rIL-10 in vitro (Carvalho et al., 2010).
This work further shows that the dextrin nanogel is
biocompatible and that is able to release rIL-10 in
biologically relevant amounts over 4 h, after sc administra-
tion in mice. It also shown that rIL-10, complexed with the
nanogel or not, is able to reduce TNF-a production after
LPS challenge in vivo.
The major limitation to this system seems to lie on the
strong interaction of rIL-10 with the nanogel, due to fast
denaturation of the cytokine in spite of the stabilizing effect
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of the nanogel. The use of additives and further stabilization
of rIL-10 is expected to improve the performance of these
formulations, allowing a controlled release over a long
period of time. Dextrin nanogels are thus a promising
system for protein delivery and more sophisticated
formulations with targeting ability are being developed.
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